Roche's medicine is required to carry a black box warning, the most serious, about the risk of blood clots. In patients under 12 years of age, emicizumab would reduce costs by about $720,000 per patient annually. Hemophilia is a rare bleeding disorder in which a clotting protein is missing or does not function normally. Roche plans to charge about $482,000 for the first year of treatment and $448,000 a year after that. To avoid joint damage and other complications, patients with severe hemophilia need regular infusions of very expensive clotting factors.

Source: Economic Times January 27, 2018 00:11 UTC